Prof. PierFranco Conte


The main objective in the drafting of the Oncology Network’s PDTA (DGR 2067/2013) is to ensure promptness, adequate levels and continuity of care throughout the care pathway: from the moment the patient enters the pathway, to the multidisciplinary evaluation of his or her tumor, until complete remission or end of life.
The preservation of a respectable quality of life, from the early stages onward, the provision of adequate support for the patient and his or her family, and the protection of the dignity and autonomy of cancer patients are an integral part of the PDTA.


The IOV is the hub of the hospital and territorial oncology network of the Veneto Region (ROV). It coordinates regional oncology care in close harmony with all hospital companies of the Veneto region. PDTA for various types of cancers have been defined and shared among the hospitals.
In the context of demand management, an organizational model that puts the cancer patient at the center and is able to respond to ethical and social needs is necessary to reduce drop-out from the defined care pathways.


Monitoring of the PDTA through specific performance indicators makes it possible to analyze cancer care across the network. It becomes, therefore, of strategic importance to identify indicators of performance within the Institute that can also be expanded to the regional level. This will make it possible to have quantitative evidence for business and healthcare planning of the Institute in order to verify the appropriateness, continuity and uniformity of care, and the quality of the services offered.
Analysis of performance indicators will allow on-site verification of improvements introduced by the PDTAs and will help guide decisions. Indicators are today identified with information obtained from the current information flows (specialist care, hospitalization, pharmaceutical, home care, regional mortality register), appropriately integrated with record linkage techniques.

Global goals

The overall goal of this research line is to evaluate the compliance to ROV PDTA indicators in patients treated at the Veneto Institute of Oncology in the various care pathways. In particular:

  1. monitoring of adherence to performance indicators;
  2. implementation of internal audits;
  3. analysis of any corrective systems.

Expected results

  • The development of an application that will provide direct access to structure and process indicator data that can be extracted from regional information flows to verify the true state of cancer patient care as defined by the various PDTAs of the Veneto Oncology Network.
  • Measurable activities used as indicators to verify results:
    • number of admissions for surgery;
    • waiting times to begin chemotherapy / post-intervention radiotherapy;
    • chemotherapy in the last 30 days of life;
    • inappropriate diagnostic tests (TAC, Magnetic Resonance, PET, etc);
    • number of audits developed.
Top 15 pubblicazioni 2019 linea 5
TitoloAutoriRivistaIF grezzo
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD)Schadendorf Dirk, Hauschild Axel, Santinami Mario, Atkinson Victoria, Mandalà Mario, chiarion sileni vanna, Larkin James, Nyakas Marta, Dutriaux Caroline, Haydon Andrew, Robert Caroline, Mortier Laurent, Lesimple Thierry, Plummer Ruth, Schachter Jacob, Dasgupta Kohinoor, Manson Stephanie, Koruth Roy, Mookerjee Bijoyesh, Kefford Richard, Dummer Reinhard, Kirkwood John M., Long Georgina V.LANCET ONCOLOGY35.386
Treatment duration of checkpoint inhibitors for NSCLCRemon Jordi, Menis Jessica, Aspeslagh Sandrine, Besse BenjaminLancet Respiratory Medicine22.992
Risk-reducing medications for primary breast cancer: a network meta-analysismocellin simone, Goodwin Annabel, Pasquali SandroCochrane Database of Systematic Reviews7.755
Uveal Melanoma Biopsy: A ReviewFrizziero Luisa, Midena Edoardo, Trainiti Sara, Londei Davide, Bonaldi Laura, Bini Silvia, Bini Silvia, Parrozzani RaffaeleCancers6.162
The Prognostic Nutritional Index Predicts Survival and Response to First-Line Chemotherapy in Advanced Biliary CancerSalati M, Filippi R, Vivaldi C, Caputo F, Leone F, Salani F, Cerma K, Aglietta M, Fornaro L, Sperti E, Di Maio M, Ortega C, Fenocchio E, Lombardi P, Cagnazzo C, Depetris Ilaria, Gelsomino F, Spallanzani A, Santini D, Silvestris N, Aprile G, Roviello G, Scartozzi M, Cascinu S, Casadei-Gardini ALIVER INTERNATIONAL5.542
From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study)Pasello Giulia, Vicario Giovanni, Zustovich Fable, Oniga Francesco, Gori Stefania, Rosetti Francesco, Bonetti Andrea, Favaretto Adolfo, Toso Silvia, Redelotti Roberta, Santo Antonio, Bernardi Daniele, Giovanis Petros, Oliani Cristina, Calvetti Lorenzo, Gatti Carlo, Palazzolo Giovanni, Baretta Zora, Bortolami Alberto, Bonanno Laura, Basso Marco, Menis Jessica, Corte Donatella Da, Frega Stefano, Guarneri Valentina, Conte Pierfranco, ON BEHALF OF VENETO ONCOLOGY NETWORKONCOLOGIST5.252
Real-World Evidence in Oncology: Opportunities and LimitationsDi Maio Massimo, Perrone Francesco, Conte PierfrancoONCOLOGIST5.252
Heterogeneous Tumor Features and Treatment Outcome Between Males and Females With Lung Cancer (LC): Do Gender and Sex Matter?Frega Stefano, Dal Maso Alessandro, Ferro Alessandra, Bonanno Laura, Conte Pierfranco, Pasello GiuliaCRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY5.012
Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelinesPassiglia F, Pilotto S, Facchinetti F, Bertolaccini L, Del Re M, Ferrara R, Franchina T, Malapelle U, Menis Jessica, Passaro A, Ramella S, Rossi G, Trisolini R, Novello SCRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY5.012
Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and PerspectivesCavallari Ilaria, Urso Loredana, Sharova Evgeniya, Pasello Giulia, Ciminale VincenzoFrontiers in Oncology4.137
New Paradigm for Stage III Melanoma: From Surgery to Adjuvant TreatmentAscierto Paolo Antonio, Borgognoni Lorenzo, Botti Gerardo, Guida Michele, Marchetti Paolo, mocellin simone, Muto Paolo, Palmieri Giuseppe, Patuzzo Roberto, Quaglino Pietro, Stanganelli Ignazio, Caracò CorradoJournal of Translational Medicine4.098
Colic and Rectal Tumors With Peritoneal Metastases Treated With Cytoreductive Surgery and HIPEC: One Homogeneous Condition or Two Different Diseases? A Systematic Review and Meta-AnalysisTonello Marco, Sommariva Antonio, Pirozzolo Giovanni, Mattara Genny, pilati pierluigiEJSO3.379
Nutritional Therapy in Cancer Patients Receiving Chemoradiotherapy: Should We Need Stronger Recommendations to Act for Improving Outcomes?Cotogni Paolo, Pedrazzoli Paolo, De Waele Elisabeth, Aprile Giuseppe, Farina Gabriella, Stragliotto Silvia, De Lorenzo Francesco, Caccialanza RiccardoJournal of Cancer3.182
Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 AnalysesLenz Heinz Josef, Argiles Guillem, Yoshino Takayuki, Lonardi Sara, Falcone Alfredo, Limón María Luisa, Sobrero Alberto, Hastedt Claudia, Peil Barbara, Voss Florian, Griebsch Ingolf, Van Cutsem EricClinical Colorectal Cancer3.176
Prevalence of Pain in Patients With Cancer Aged 70 Years or Older: A Prospective Observational StudyBrunello Antonella, AHCENE DJABALLAH SELMA, Lettiero Annunziata, Tierno Giuseppina, Fiduccia Pasquale, Guglieri Irene, Dadduzio Vincenzo, Maruzzo Marco, Schiavon Stefania, Lonardi Sara, zagonel vittorinaJournal of Geriatric Oncology3.164

Source: IOV Scientific library

Top 15 pubblicazioni 2018 linea 5
TitoloAutoriRivistaIF grezzo
Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME)Imbimbo M., Ottaviano M., Vitali M., Fabbri A., Leuzzi G., Fiore M., Franceschini D., Pasello Giulia, Perrino M., Schiavon M., Pruneri G., Dei Tos A.P., Sangalli C., Garassino M.C., Berardi R., Alessi A., Calareso G., Petrini I., Scorsetti M., Scotti V., Rosso L., Rea F., Pastorino U., Casali P.G., Ramella S., Ricardi U., Abate-Daga L., Torri V., Trama A., Palmieri G., Marino M., Zucali P.A., collaborators TYME networkCANCER TREATMENT REVIEWS8.122
A prospective comparative trial of adjunct screening with tomosynthesis or ultrasound in women with mammography-negative dense breasts (ASTOUND-2)Tagliafico Alberto S, Mariscotti Giovanna, Valdora Francesca, Durando Manuela, Nori Jacopo, La Forgia Daniele, Rosenberg Ilan, Caumo Francesca, Gandolfo Nicoletta, Sormani Maria Pia, Signori Alessio, Calabrese Massimo, Houssami NehmatEUROPEAN JOURNAL OF CANCER7.191
Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trialInvestigators ICOS-ONE Study, Cardinale Daniela, Ciceri Fabio, Latini Roberto, Franzosi Maria Grazia, Sandri Maria Teresa, Civelli Maurizio, Cucchi Gian Franco, Menatti Elisabetta, Mangiavacchi Maurizio, Cavina Raffaele, Barbieri Enrico, Gori Stefania, Colombo Alessandro, Curigliano Giuseppe, Salvatici Michela, Rizzo Antonio, Ghisoni Francesco, Bianchi Alessandra, FALCI CRISTINA, Aquilina Michele, Rocca Andrea, Monopoli Anna, Milandri Carlo, Rossetti Giuseppe, Bregni Marco, Sicuro Marco, Malossi Alessandra, Nassiacos Daniele, Verusio Claudio, Giordano Monica, Staszewsky Lidia, Barlera Simona, Masson Serge, Cipolla Carlo M., Maggioni A. P., Tettamanti M., Pellegrini C., Scognamiglio G., Corrado G., De Rosa F., Callegari S., Fodor C., Mazza R., Sala E., Fragasso G., Farolfi A., Andreis D., Gervasi E., Barco B.EUROPEAN JOURNAL OF CANCER7.191
First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast CancerDieci Maria Vittoria, Guarneri Valentina, Giarratano Tommaso, Mion M., Tortora G., De Rossi C., Gori Stefania, Oliani C., Merlini L., Pasini F., Bonciarelli G., Griguolo G., Orvieto E., michieletto silvia, saibene tania, Del Bianco Paola, De Salvo Gian Luca, Conte PierfrancoONCOLOGIST5.306
Changes in food habits in cancer patients in Italy: a survey. AIOM - SINPE - FAVOgroup AIOM-SINPE-FAVO working, Gavazzi Cecilia, Sieri Sabina, Tracl¿¿ Francesca, Sproviero Alessandro, Vandoni Giulia, Ricci Roberta, Stragliotto Silvia, zagonel vittorinaNUTRITION3.734
Quality assurance and sustainability of cancer care A European network is neededRossi Carlo Riccardo, Sommariva Antonio, Bastiaannet Esther, Van De Velde Cornelis J HEJSO3.688
Quality assurance in melanoma care The EU-MELACARE studySommariva Antonio, Forsea Ana-Maria, Agius Domenic, Ascierto Paolo Antonio, Bastiaannet Esther, Borgognoni Lorenzo, Demetriou Anna, Garbe Claus, Gavric Zivana, Hocevar Marko, Innos Kaire, Lar¿¿nningen Siri, Louwman Marieke, Robsahm Trude Eid, Rutkwoski Piotr, van Akkooi Alexander, Zorzi Manuel, Pasquali Sandro, van de Velde Cornelis, Rossi Carlo RiccardoEJSO3.688
Comparison of breast cancers detected in the Verona screening program following transition to digital breast tomosynthesis screening with cancers detected at digital mammography screeningCaumo Francesca, Romanucci Giovanna, Hunter Kylie, Zorzi Manuel, Brunelli Silvia, Macaskill Petra, Houssami NehmatBREAST CANCER RESEARCH AND TREATMENT3.605
Social relationship coping efficacy A new construct in understanding social support and close personal relationships in persons with cancerMerluzzi Thomas V, Serpentini Samantha, Philip Errol J, Yang Miao, Salamanca-Balen Natalia, Heitzmann Ruhf Carolyn A, Catarinella AntonioPSYCHO-ONCOLOGY3.455
Quality of Life Perception, Cognitive Function, and Psychological Status in a Real-world Population of Glioblastoma Patients Treated With Radiotherapy and Temozolomide A Single-center Prospective StudyLOMBARDI GIUSEPPE, Bergo Eleonora, Del Bianco Paola, Bellu Luisa, Pambuku Ardi, Caccese Mario, Trentin Leonardo, zagonel vittorinaAMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS3.424
The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patientsBattaglin Francesca, schirripa marta, Buggin Federica, Pietrantonio Filippo, Morano Federica, Boscolo Giorgia, Tonini Giuseppe, Lutrino Eufemia Stefania, Lucchetti Jessica, Salvatore Lisa, Passardi Alessandro, Cremolini Chiara, Arnoldi Ermenegildo, Scartozzi Mario, Pella Nicoletta, Boni Luca, Bergamo Francesca, zagonel vittorina, Loupakis Fotios, Lonardi SaraBMC CANCER3.288
Estimation of Direct Melanoma-related Costs by Disease Stage and by Phase of Diagnosis and Treatment According to Clinical GuidelinesBuja Alessandra, Sartor Gino, Scioni Manuela, Vecchiato Antonella, Bolzan Mario, Rebba Vincenzo, chiarion sileni vanna, Palozzo Angelo Claudio, montesco maria, Del Fiore Santo Paolo, Baldo Vincenzo, Rossi Carlo RiccardoACTA DERMATO-VENEREOLOGICA3.127
An exploratory radiomics analysis on digital breast tomosynthesis in women with mammographically negative dense breastsTagliafico Alberto Stefano, Valdora Francesca, Mariscotti Giovanna, Durando Maunela, Nori Jacopo, La Forgia Daniele, Rosenberg Ilan, Caumo Francesca, Gandolfo Nicoletta, Houssami Nehmat, Calabrese MassimoBREAST2.951
Interval breast cancers in the 'screening with tomosynthesis or standard mammography' (STORM) population-based trialHoussami Nehmat, Bernardi Daniela, Caumo Francesca, Brunelli Silvia, Fant¿¿ Carmine, Valentini Marvi, Romanucci Giovanna, Gentilini Maria A, Zorzi Manuel, Macaskill PetraBREAST2.951
Is there a correlation between 3T multiparametric MRI and molecular subtypes of breast cancer?Montemezzi Stefania, Camera Lucia, Giri Maria Grazia, Pozzetto Alice, Cali¿¿ Anna, Meliad¿¿ Gabriele, Caumo Francesca, Cavedon CarloEUROPEAN JOURNAL OF RADIOLOGY2.843

Source: IOV Scientific library